



Scholars Research Library

Der Pharma Chemica, 2011, 3(1): 167-171

(<http://derpharmachemica.com/archive.html>)



ISSN 0975-413X
CODEN (USA): PCHHAX

Synthesis and antimicrobial studies of some novel pyrazolines

S.Shah N.N.¹, Biradar A.S.¹, Seema I Habib¹, Dhole J.A.², M.A.Baseer¹ and Kulkarni P.A.^{1*}

¹Laboratory of Organic Synthesis, P.G. Department of Studies in Chemistry, Yeshwant College, Nanded (M.S.) INDIA

²Department of Botany, Yeshwant College Nanded, (M.S.) INDIA

ABSTRACT

The Chalcones Condensed with hydrazine hydrate in ethanol to get the corresponding novel pyrazolines (I-X). The compounds were synthesized and characterized by TLC, melting points, IR, ¹H-NMR and mass spectra. The synthesized compounds have been screened for their antimicrobial activity against different micro-organisms. All the compounds show moderate to good activity against different micro-organisms.

Keywords: Chalcones, Hydrazine hydrate, Pyrazolines, Antimicrobial Activity.

INTRODUCTION


Pyrazolines are well known biologically important nitrogen containing heterocycles. Nitrogen containing heterocyclic compounds [1] like pyrazolines have received considerable attention in recent years. Pyrazolines exhibit a plethora of bioactivities viz, COX-2 inhibitor[2], antiandrogenic[3], antibacterial[4], antifungal[5], antitumor[6], antidepressant[7], insecticidal[8], antidiabetic[9], photochemical[10], herbicidal[11], molluscicidal[12], antinociceptive[13] and antiamebic activity[14]. Pyrazolines are also used in the treatment of Parkinson's, Alzheimer's disease and Cerebral edema[15]. Besides Being Biologically active they are also used as useful synthons in organic synthesis[16-18]. Hence synthesis of Pyrazolines are largely on account of their biological activity. Herein we report the synthesis of some novel pyrazolines by using the chalcones and hydrazine hydrate.

MATERIALS AND METHODS


Experimental

Melting points were determined in open capillary tubes and are uncorrected. Purity of the compounds was checked by TLC on silica gel G. UV light or iodine vapour accomplished

visualization. The IR Spectra were recorded on FTIR perkin-Elmer 1420 spectrometer and PMR spectra (CDCl_3) on a varian-300 MHz spectrometer using TMS as internal standard. Mass spectra were recorded on VG 7070 H Mass spectrometer at 70 eV.



Entry	R ₁	R ₂	R ₃
I	H	Br	
II	H	Br	
III	H	Br	
IV	H	Br	
V	H	Br	
VI	OMe	H	
VII	Br	H	



General Procedure for synthesis of Pyrazolines:

A solution of chalcones (0.01 mole) in ethanol (20ml) and hydrazine hydrate (99%, 0.01 mole) was refluxed for 2 to 3 hr. After completion of the reaction some solvent distilled out under reduced pressure. The reaction mixture was cooled, the solid separated was collected and recrystallized from ethanol.

RESULTS AND DISCUSSION

The most common synthetic approach to pyrazoline synthesis involves cyclization of propenones with hydrazines in the presence of acetic acid as cyclizing agent.[19]. Herein we reported the synthesis of novel pyrazolines by condensing chalcones with hydrazine hydrate in ethanol. The newly synthesized compounds evaluated for antimicrobial activity. Structures of newly synthesized compounds were confirmed by spectral analysis.

Compound VI

5-[5-(4-Methoxy-phenyl)-3,4-dihydro-2H-pyrazol-3-yl]-2-nitro-phenol:

IR(KBr):1150 cm^{-1} (OCH₃), 1622 cm^{-1} (C=N), 3400 cm^{-1} (N-H), 1518 cm^{-1} (N-O) , 1220 cm^{-1} (C-N); ¹HNMR(CDCl₃): δ 2.9(dd, 1H, H_a), δ 3.4(dd, 1H, H_b), δ 3.8(s, 3H ,CH₃), δ 4.8(dd, 1H ,H_x), δ 5.9(s, 1H ,NH), δ 6.8-8.2 (m, 7H ,Ar-H), δ 10.5(s, 1H ,OH). MS: MI=(m=313, m+1=314).

Table1. Physical data of synthesized pyrazolines compounds (I-X)

Entry	Molecular formula	Yield (%)	Melting point (°C)
I	C ₁₄ H ₁₃ BrN ₂ S	78	130
II	C ₁₄ H ₁₃ BrN ₂ S	85	125
III	C ₁₅ H ₁₂ BrN ₃ O ₃	88	135
IV	C ₁₅ H ₁₂ BrN ₂ F	87	220
V	C ₁₆ H ₁₄ Br ₂ N ₂ O	88	113
VI	C ₁₆ H ₁₅ N ₃ O ₄	78	145
VII	C ₁₄ H ₁₃ BrN ₂ S	86	160
VIII	C ₁₄ H ₁₃ BrN ₂ S	79	144
IX	C ₁₆ H ₁₄ Br ₂ N ₂ O	83	86
X	C ₁₅ H ₁₂ BrN ₃ O ₃	90	146

Compound VIII**3-(4-Bromo-phenyl)-5-(3-methyl-thiophen-2-yl)-4,5-dihydro-1H-pyrazoline:**

IR(KBr): 1620 cm^{-1} (C=N), 3447 cm^{-1} (N-H), 1190 cm^{-1} (C-N); $^1\text{HNMR}(\text{CDCl}_3)$: 2.15(s, 3H, CH_3), δ 2.85(dd, 1H, H_a), δ 3.3(dd, 1H, H_b), δ 5.1(dd, 1H, H_x), δ 6.0(s, 1H, NH), δ 6.7-7.7 (m, 6H, Ar-H); MS: MI= (m=321, m+2=323).

Antimicrobial activity

Antimicrobial screening of synthesized pyrazolines compounds (I-X) was conducted by using cup plate method [20-21] at a concentration of 100 $\mu\text{g/ml}$. The compounds were evaluated for antibacterial activity against *Bacillus subtilis* gr +ve, *Pseudomonas aeruginosa* gr -ve, *Staphylococcus aureus* gr +ve, *Escherichia coli* gr -ve and antifungal activity against *Aspergillus niger*, *Aspergillus Flavus*, *Curvularia*, *Alternaria*. DMSO was used as solvent control. The results of antimicrobial data are summarized in table 2. All compounds show the moderate to good activity against bacteria and fungi.

Table 2: Antimicrobial activity of synthesized Pyrazolines compounds (I-X)

Products	Bacteria (Zone of Inhibition in mm)				Fungi (Zone of Inhibition in mm)			
	A	B	C	D	E	F	G	H
I	19	21	08	17	---	---	26	17
II	23	21	18	18	11	10	21	20
III	24	17	27	20	14	---	17	10
IV	11	---	12	---	12	15	11	---
V	16	34	14	24	---	---	21	14
VI	14	16	15	17	---	---	16	---
VII	16	19	15	19	17	10	19	13
VIII	13	17	10	11	11	---	09	---
IX	13	14	09	15	---	---	14	15
X	18	24	16	12	18	13	19	15

A= *Bacillus subtilis* gr +ve, B= *Pseudomonas aeruginosa* gr -ve, C= *Staphylococcus aureus* gr +ve, D= *Escherichia coli* gr -ve, E= *Aspergillus niger*, F= *Aspergillus Flavus*, G= *Curvularia* H= *Alternaria*.

CONCLUSION

In summary, we have synthesized some novel pyrazolines. The newly synthesized pyrazolines are characterized by spectral data and further evaluated for antimicrobial activity. All compounds show moderate to good activity.

Acknowledgements

The authors are thankful to Principal Yeshwant College, Nanded for providing lab facilities for the research work.

REFERENCES

- [1] Oza H. B., Joshi D. G., Parikh H. H., *Heterocyclic Comm.*, **1997**, 3,3.
- [2] Norris T., Colon-Cruz R., Ripin D. H. B., *Org. Biomol. Chem.*, **2005**, 3,1844.
- [3] Zhang X., Li X., Allan G. F., Sbriscia T., *J. Med. Chem.*, **2007**, 50(16),3857.
- [4] Jamode V. S., Thakre D.V., *Asian J. Chemistry*, **2003**,15(3 and 4), 1808.

- [5] Korgaokar S.S., Patil P.H., Shah M. T., Parekh H.H., *Indian J.Pharm. Sci.*, **1996**,58, 222.
- [6] Taylor E.C., Patel H., Kumar H., *Tetrahedron*, **1992**,48, 8089.
- [7] Ruhoglu O., Ozdemir Z., Calis U., Gumusel B., Bilgin A.A., *Arzneim Forsch*, **2005**, 55(8) 431.
- [8] *US Patent 4095026*
- [9] Soliman R., Faid-Allah H. M., el-Sadany S.K., *J. Pharm. Sci.*, **1987**, 76(8),626.
- [10] Ji S.J. & Shi H.B., *Dyes Pigments* **2006**, 70(3),246.
- [11] Moimoto K.M., Makino K., Yamamoto S., Sakoto G., *J. Heterocycl Chem*, **1990**, 27, 807.
- [12] Mishriky N., Asaad F. M., Ibrahim Y.A., Girgis A.S., *Pharmazie*, **1996**, 51(8), 544.
- [13] Shafiee A., Bagheri M., Shekarchi M. & Abdollahi M., *J Phar Pharmaceut Sci*, **2003**, 6(3),360.
- [14] Abid M., Azam A., *Bioorg Med Chem*, **2006**, 16(10),2812.
- [15] Kawazura H., Takahashi Y., Shiga Y., Shimad F., Ohto N., Tamura A., *Jpn. J. Pharmacol* **1997**, 73(4),317
- [16] Klimova E.I., Marcos M., Klimova T. B., Cecilio A.T., Ruben A.T., Lena R. R., *J. Organomet. Chem*, **1999**, 585,106.
- [17] Padmavathi V., Sumathi R.P., Chandrasekhar B.N. , Bhakarreddy D., *J. Chem. Res.* **1999**, 610
- [18] Bhaskarreddy D., Chandrasekhar B.N., Padmavathi V.. Sumathi R.P., *Synthesis*, **1998**,491.
- [19] Baker W., Butt V. S., *J.chem. Soc.* **1949**,2142.
- [20] Banty A.L., *The Antimicrobial Susceptibility Test: Principle and Practice*, Ed., by Illus Lea and Febiger (Philadelphia, PA, USA), **1976**, 180.
- [21]. Seely H.W. and Van Demark P.J., *Microbes in Action: A Laboratory Manual of Microbiology*, D.B.Taraporewala Sons and Co., Bombay, **1975**, 55.